



## Investor News 2014

The news contents can be obtained from our website [www.investor.bayer.com](http://www.investor.bayer.com)

Date	News
December 17, 2014	Not intended for U.S. and UK Media <b>Bayer Submits Application for U.S. FDA Approval for Recombinant Factor VIII Product (BAY 81-8973) for the Treatment of Hemophilia A in Adults and Children</b>
December 04, 2014	Not intended for U.S. and UK Media <b>Bayer Submits Marketing Authorization Application in Europe for Recombinant Factor VIII Product (BAY 81-8973) for the Treatment of Hemophilia A in Adults and Children</b>
December 01, 2014	Not intended for U.S. and UK Media - American Society of Hematology 56th Annual Meeting and Exposition 2014: <b>Bayer to Present Latest Data on Its Hematology and Oncology Portfolio</b> - Three-year results from the Phase III SPINART study for octocog alfa (Kogenate® FS) in patients with hemophilia A - New data on damoctocog alfa pegol (BAY 94-9027) for the treatment of hemophilia A - Presentations on copanlisib and sorafenib in patients with different hematological cancers
November 18, 2014	Not intended for U.S. and UK Media <b>Bayer Receives Approval for EYLEA® in Diabetic Macular Edema in Japan</b>
November 13, 2014	Not intended for U.S. and UK Media <b>Bayer to Evaluate sGC Stimulator Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis</b> Phase II study initiated to investigate riociguat in new indication beyond pulmonary hypertension
November 3, 2014	Not intended for U.S. and UK Media <b>Bayer completes acquisition of Dihon Pharmaceutical Group Co., Ltd. in China</b> Transaction strengthens Consumer Care business and moves Bayer HealthCare to a leading OTC position in key growth country
October 30, 2014	Third quarter of 2014: <b>Bayer operationally strong - strategic focus on Life Science businesses</b> - Sales advance in all subgroups - double-digit percentage growth for CropScience and the Pharmaceuticals Division (Fx & portfolio adj.) - Group sales EUR 10,187 million (plus 5.6 percent / Fx & portfolio adj.: plus 7.4 percent) - EBIT improves by 12.7 percent to EUR 1,376 million - EBITDA before special items increases by 1.4 percent to EUR 2,011 million - Net income advances by 12.7 percent to EUR 826 million - Core earnings per share grow by 6.3 percent to EUR 1.35 - Guidance for full year 2014 raised - Plan to float MaterialScience on the stock market
October 8, 2014	<b>Professor Otmar D. Wiestler appointed to the Supervisory Board of Bayer AG</b> Dr. Klaus Kleinfeld concentrating on other offices and honorary posts, some in the USA

- October 2, 2014 **Bayer launches jumbo bond issuance with a volume of USD 7 billion**  
 - Successful placement as part of the financing of the acquisition of the OTC business of Merck & Co., Inc., United States  
 - Six tranches with maturities of two to ten years
- October 1, 2014 **Bayer closes acquisition of consumer care business of Merck & Co., Inc., United States, for USD 14.2 billion**  
 - Bayer becomes the OTC leader in North and Latin America and achieves top global positions in key OTC categories  
 - Erica Mann heads Bayer's new consumer care business  
 - Course set for successful integration  
 - Strategic pharma collaboration between Bayer und Merck & Co., Inc. in the field of sGC modulators takes effect
- September 24, 2014 Not intended for U.S. and UK Media  
**ESMO 2014 to Feature New Oncology Data from Across Bayer Franchise**  
 - Positive Results of the Phase III CONCUR trial of regorafenib in Asian patients with metastatic colorectal cancer to be presented in Proffered Paper Session  
 - Includes data from studies evaluating regorafenib, sorafenib and radium Ra 223 dichloride across six tumor types
- September 22, 2014 Not intended for U.S. and UK Media  
**Bayer Receives Approval for EYLEA® for the Treatment of Myopic Choroidal Neovascularization in Japan**
- September 18, 2014 Strategic corporate decision:  
**Bayer Board of Management plans to focus entirely on Life Science businesses**
- September 18, 2014 **Bayer plans to focus entirely on Life Science businesses**  
 - Concentration on HealthCare and CropScience  
 - MaterialScience to be floated on the stock market by 2016 at the latest  
 - Planned separation to benefit both Bayer and MaterialScience  
 - Employment levels are expected to remain stable over the next few years
- September 17, 2014 **Demand for innovative solutions for Sustainable Agriculture drives Bayer CropScience**  
 - Bayer CropScience expects market for agricultural inputs to grow to EUR 100 billion despite increasing volatility  
 - Company continues to invest significantly in innovative solutions for continued growth  
 - Long-term innovation program to enhance global wheat productivity  
 - New public dialogue program to foster communication with society about modern agriculture
- September 16, 2014 Not intended for U.S. and UK Media  
**Bayer and Orion Initiate Phase III Trial of Novel Prostate Cancer Agent ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer**
- September 8, 2014 Not intended for U.S. and UK Media - Two-year data presented at European Respiratory Society (ERS) Congress 2014:  
**Safety and Sustained Benefits of Adempas® From Bayer Confirmed by Results of Long-Term Studies**  
 - Analysis of long-term extension studies CHEST-2 and PATENT-2 confirms long-term safety profile of riociguat over two years in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH)  
 - Results demonstrate sustained improvements with riociguat in patients with CTEPH and PAH
- September 4, 2014 Not intended for U.S. and UK Media - Treatment of macular edema secondary to branch retinal vein occlusion (BRVO):  
**Bayer Submits New Application for Aflibercept Solution for Injection into the Eye in Japan Based on Phase 3 Data in Patients with BRVO**  
 Aflibercept Solution for Injection met primary endpoint of the Phase 3 VIBRANT study

September 2, 2014 Not intended for U.S. and UK Media - Hot Line Session at European Society of Cardiology (ESC) Congress 2014:  
**Once-Daily Xarelto® from Bayer Effective and Well-Tolerated Alternative to Vitamin K Antagonists in Protecting Patients with Atrial Fibrillation who Undergo Cardioversion**  
- X-VeRT is the first prospective study of a novel oral anticoagulant in patients with atrial fibrillation who undergo cardioversion  
- X-VeRT provides important information on the utility and practical advantages of Xarelto in early and delayed cardioversion over the use of vitamin K antagonists  
- X-VeRT is part of the extensive ongoing evaluation of rivaroxaban that will include more than 275,000 patients in both clinical trials and real world settings

September 2, 2014 **Bayer closes on divestiture of Interventional device business to Boston Scientific**

August 29, 2014 Not intended for U.S. and UK Media  
**Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism**  
New studies expand investigation of rivaroxaban to more than 275,000 patients

August 25, 2014 Not intended for U.S. and UK Media - European Society of Cardiology (ESC) Congress 2014:  
**New Data on Xarelto® (Rivaroxaban) from Bayer accepted for ESC Congress 2014 Hot Line Session**  
- Results from X-VeRT, the first prospective study of a novel oral anticoagulant in patients with atrial fibrillation undergoing cardioversion will be presented during ESC Congress 2014 Hot Line Session  
- Sub-analyses from ROCKET AF and ATLAS ACS 2-TIMI 51 to provide further insights into clinical utility of Xarelto  
- Independently, the Thrombosis Research Institute (TRI) will present data from the GARFIELD AF Registry, an academic research initiative, supported through an unrestricted educational grant from Bayer

August 11, 2014 Not intended for U.S. and UK Media  
**Bayer Receives EU Approval for EYLEA® in Diabetic Macular Edema**

July 30, 2014 Second quarter of 2014:  
**Bayer continues positive business development**  
- Sales growth in all subgroups  
- Group sales EUR 10,458 million (plus 0.9 percent; Fx & portfolio adj. plus 6.3 percent)  
- EBIT improves by 14.5 percent to EUR 1,473 million  
- EBITDA before special items increases by 1.0 percent to EUR 2,217 million - despite negative currency effects of 7 percent  
- Net income advances by 13.3 percent to EUR 953 million  
- Core earnings per share level with prior year at EUR 1.53 (minus 0.6 percent)  
- Group outlook for 2014 confirmed

July 30, 2014 Not intended for U.S. and UK Media  
**Stivarga® (regorafenib) from Bayer Approved in the European Union for the Treatment of Gastrointestinal Stromal Tumors**  
- Approval in the second indication for Stivarga in the EU within one year  
- Decision based on positive results from Phase III GRID trial in which regorafenib significantly extended progression-free survival

July 25, 2014 Not intended for U.S. and UK Media  
**Phase III Trial of Sorafenib in Combination with Capecitabine Does Not Meet Primary Endpoint in Patients with Advanced Breast Cancer**

July 18, 2014 Not intended for U.S. and UK Media - Aflibercept solution for injection into the eye:  
**Two-Year Results From Phase 3 Trial Show Sustained Improvement in Vision for People with Diabetic Macular Edema**

June 27, 2014 Not intended for U.S. and UK Media  
**Regorafenib from Bayer Recommended for Approval in the European Union for the Treatment of Gastrointestinal Stromal Tumors**  
Final decision from European Commission expected in the third quarter of 2014

June 27, 2014 Not intended for U.S. and UK Media - Aflibercept solution for injection into the Eye:  
**Bayer Receives positive CHMP Opinion for the Treatment of Visual Impairment due to Diabetic Macular Edema in EU**

June 25, 2014 Not intended for U.S. Media - To finance the acquisition of the consumer care business of Merck & Co., Inc.  
**Bayer issues hybrid capital of EUR 3.25 billion**  
Largest corporate euro hybrid bond transaction worldwide

June 21, 2014 Not intended for UK Media  
**Bayer HealthCare and Dimension Therapeutics to Develop Novel Gene Therapy for Hemophilia A**

June 20, 2014 Not intended for U.S. and UK Media  
**Bayer Receives Approval for Nexavar® (sorafenib) in Japan for Treatment of Differentiated Thyroid Cancer**  
Approval based on positive data from Phase III DECISION trial, in which sorafenib significantly extended progression-free survival

June 11, 2014 Not intended for U.S. and UK Media - Treatment of visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO):  
**Bayer Submits Aflibercept Solution for Injection Into the Eye for Fourth Indication in EU**

June 05, 2014 **Dieter Weinand to become President of Bayer HealthCare Pharmaceuticals**

June 03, 2014 Not intended for U.S. and UK Media  
**Bayer to Evaluate Riociguat in New Indication**  
Phase IIb Study Initiated to Investigate Riociguat in Pulmonary Hypertension associated with Idiopathic Interstitial Pneumonia

June 03, 2014 Resolutions of the Supervisory Board of Bayer AG  
**Contract for CEO Dr. Marijn Dekkers extended to the end of 2016**  
- Werner Baumann appointed as Chief Strategy and Portfolio Officer  
- Johannes Dietsch to be Chief Financial Officer

June 02, 2014 Not intended for U.S. and UK Media  
**Bayer and Orion Corporation to develop and commercialize novel prostate cancer treatment**

May 30, 2014 Not intended for U.S. and UK Media  
**Bayer Receives EU Approval for Nexavar® (sorafenib) for the Treatment of Differentiated Thyroid Cancer**  
- Nexavar is the only treatment approved in Europe and the United States for patients with this type of thyroid cancer  
- Nexavar significantly extended progression-free survival compared to placebo in Phase III DECISION trial

May 28, 2014 Not intended for U.S. and UK Media  
**Xarelto™ from Bayer Submitted in Japan for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism as well as for the Prevention of Recurrent Venous Thromboembolism**  
- Submission supported by successful global and Japanese EINSTEIN studies  
- Oral single-drug approach with rivaroxaban proven effective for the treatment of deep vein thrombosis and pulmonary embolism

May 28, 2014 **Andreas Fibig to leave Bayer HealthCare Pharmaceuticals**

May 15, 2014	<p><b>Bayer to divest Interventional device business to Boston Scientific for \$415 million</b></p> <ul style="list-style-type: none"> <li>- Divestiture includes AngioJet (thrombectomy) and Jetstream (atherectomy) systems, and the Fetch2 Aspiration Catheter</li> <li>- Bayer HealthCare's Medical Care division to focus on innovation and growth in Radiology and Diabetes Care business areas</li> </ul>
May 06, 2014	<p>Move to significantly strengthen position in consumer care</p> <p><b>Bayer to acquire consumer care business of US-based Merck &amp; Co., Inc. and to engage in strategic pharma cooperation in the field of sGC modulators</b></p> <ul style="list-style-type: none"> <li>- Purchase price of USD 14.2 billion in cash for Merck &amp; Co., Inc.'s consumer care business</li> <li>- Bayer to become the OTC leader in North America and Latin America and achieve top global positions in key OTC product categories</li> <li>- Strategic pharma collaboration with Merck &amp; Co., Inc. in the field of sGC modulators for which Bayer will receive a USD 1 billion upfront payment, plus substantial additional sales milestones</li> </ul>
April 29, 2014	<p>CEO Dr. Marijn Dekkers at the Annual Stockholders' Meeting of Bayer AG:</p> <p><b>Bayer targets further growth with innovative products</b></p> <ul style="list-style-type: none"> <li>- Successful course maintained in anniversary year 2013</li> <li>- Dividend increase to EUR 2.10 per share for 2013 proposed</li> <li>- Employees to share in the company's success with total bonuses of over EUR 650 million</li> <li>- Encouraging start to 2014</li> </ul>
April 28, 2014	<p>First quarter of 2014</p> <p><b>Bayer: Very successful start to 2014</b></p> <ul style="list-style-type: none"> <li>- Encouraging business development in all subgroups</li> <li>- Strong growth for recently launched pharmaceutical products</li> <li>- Group sales EUR 10,555 million (plus 2.8 percent, Fx &amp; portfolio adj. plus 8.4 percent)</li> <li>- EBIT moves ahead by 18.4 percent to EUR 2,096 million</li> <li>- EBITDA before special items rises by 11.6 percent to EUR 2,738 million – despite negative currency effects of 8 percent</li> <li>- Net income advances by 22.7 percent to EUR 1,423 million</li> <li>- Core earnings per share increase by 14.7 percent to EUR 1.95</li> <li>- Forecast for 2014 confirmed</li> </ul>
April 25, 2014	<p>Not intended for U.S. and UK Media</p> <p><b>Sorafenib Recommended for Approval in the European Union for the Treatment of Differentiated Thyroid Cancer</b></p> <p>Final decision from European Commission expected by mid-2014</p>
April 23, 2014	<p>Not intended for U.S. and UK Media</p> <p><b>Bayer Submits Riociguat for the Treatment of Pulmonary Arterial Hypertension in Japan</b></p>
April 04, 2014	<p>Not intended for U.S. and UK Media - 105th Annual Meeting American Association for Cancer Research</p> <p><b>Bayer to Present New Data on Advancing Oncology Portfolio</b></p> <p>New Preclinical and Early Clinical Data Evaluating Innovative Compounds in Drug Development</p>
April 02, 2014	<p>Not intended for U.S. and UK Media</p> <p><b>Bayer Initiates Phase III Trial of Radium-223 Dichloride in Combination with Abiraterone Acetate for Patients with Metastatic Castration-Resistant Prostate Cancer</b></p>
March 31, 2014	<p>Not intended for U.S. and UK Media</p> <p><b>Bayer's Adempas® (riociguat) Approved for the Treatment of Two Life-Threatening Forms of Pulmonary Hypertension in the EU</b></p> <ul style="list-style-type: none"> <li>- Adempas® is approved for patients with chronic-thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH)</li> <li>- Adempas® is the first and only drug approved to treat patients with CTEPH</li> </ul>

March 31, 2014	<p>Not intended for U.S. and UK Media - Treatment and Prevention of Venous Thromboembolism:</p> <p><b>Bayer Initiates Two New Phase III Trials to Evaluate Rivaroxaban in Medically-ill Patients and Children at High Risk of Blood Clots</b></p> <ul style="list-style-type: none"> <li>- MARINER trial to evaluate rivaroxaban for venous thromboembolism prevention in high-risk medically-ill patients following hospital discharge</li> <li>- EINSTEIN JUNIOR study will investigate rivaroxaban for the treatment and secondary prevention of venous thromboembolism in children</li> </ul>
March 13, 2014	<p>Not intended for U.S. and UK Media - Pulmonary Arterial Hypertension (PAH):</p> <p><b>Start of Phase IIIb Study with Bayer's Riociguat in PAH Patients Who Demonstrate an Insufficient Response to PDE-5 Inhibitors</b></p>
March 12, 2014	<p>Meet Management" investor conference:</p> <p><b>Bayer aspires to further sales and earnings growth through 2016</b></p> <ul style="list-style-type: none"> <li>- HealthCare: significant increases in sales and margins, mainly thanks to recently launched pharmaceutical products</li> <li>- CropScience aims to grow faster than the market and keep margin at a high level</li> <li>- MaterialScience expects improvement in profitability</li> </ul>
March 11, 2014	<p>Not intended for U.S. and UK Media</p> <p><b>Phase III Trial of Sorafenib as Adjuvant Therapy for Liver Cancer Did Not Meet Primary Endpoint</b></p>
March 11, 2014	<p>Not intended for U.S. and UK Media</p> <p><b>Bayer to invest more than 500 million Euros for the manufacturing of hemophilia A products currently in development</b></p> <p>Expansion of manufacturing capacities for innovative therapy options</p>
March 10, 2014	<p>Not intended for U.S. and UK Media</p> <p><b>Bayer to Sell Back Rights to ATX-101 to KYTHERA</b></p>
March 06, 2014	<p>Not intended for U.S. and UK Media</p> <p><b>Bayer completes voluntary takeover offer for Algeta</b></p> <ul style="list-style-type: none"> <li>- Bayer holds 98.2 % of Algeta shares after closing</li> <li>- Compulsory acquisition process planned in the coming days</li> </ul>
March 03, 2014	<p>Not intended for U.S. and UK Media</p> <p><b>Bayer Submits VEGF Trap-Eye ( aflibercept solution for injection) for Treatment of Diabetic Macular Edema in Japan</b></p>
February 28, 2014	<p>Fiscal 2013:</p> <p><b>Bayer continues successful course in anniversary year</b></p> <ul style="list-style-type: none"> <li>- Dynamic development in the Life Science businesses, MaterialScience below expectations</li> <li>- Outstanding growth for recently launched pharmaceutical products - estimate of combined peak annual sales potential for the five products increased to at least EUR 7.5 billion</li> <li>- Group sales EUR 40,157 million (plus 1.0 percent; Fx &amp; portfolio adj.: plus 5.1 percent)</li> <li>- EBIT advanced by 25.6 percent to EUR 4,934 million</li> <li>- EBITDA before special items up by 1.5 percent to EUR 8,401 million</li> <li>- Net income increased 32.7 percent to EUR 3,189 million</li> <li>- Core earnings per share up 5.8 percent to EUR 5.61</li> <li>- Forecast for 2014: further growth in sales and earnings</li> </ul>
February 27, 2014	<p>Not intended for U.S. and UK Media</p> <p><b>Bayer to acquire Dihon Pharmaceutical Group Co., Ltd. in China</b></p> <p>Transaction strengthens Consumer Care business and moves Bayer HealthCare to a leading OTC position in key growth country</p>
February 26, 2014	<p><b>Bayer proposes increased dividend for 2013 of EUR 2.10 per share</b></p> <p>Total dividend payout rises 10.6 percent to EUR 1,737 million</p>

February 26, 2014 Not intended for U.S. and UK Media - Acceptance level at 97.28 %:  
**Bayer: Takeover offer for Algeta successful**  
- Compulsory acquisition and delisting intended  
- Takeover expected to be completed in the first quarter of 2014

February 24, 2014 Not intended for U.S. and UK Media  
**Bayer extends offer period for Algeta takeover offer**  
- Offer period now ends on February 26, 2014 at 09:00 CET  
- Cash offer of NOK 362 per Algeta share unchanged  
- Preliminary acceptance level of 92.17 % of Algeta's share capital

February 20, 2014 Not intended for U.S. and UK Media  
**Bayer Initiates Phase III Trial of Regorafenib in Patients with Colorectal Cancer after Resection of Liver Metastases**

February 18, 2014 Not intended for U.S. and UK Media  
**Bayer's Long-Acting Recombinant Factor VIII Demonstrated Effective Prophylaxis with Less Frequent Infusions in Hemophilia A in Phase III Trial**  
- In the PROTECT VIII study, BAY94-9027 met its primary efficacy and safety objectives for the treatment of patients with hemophilia A  
- Extending infusion intervals up to seven days resulted in protection from bleeds comparable to current prophylactic dose regimens  
- No patient developed inhibitors to factor VIII during the 36-week treatment period

February 17, 2014 Not intended for U.S. and UK Media - Long-term prevention of venous blood clots (VTE):  
**Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long-Term VTE Prevention**  
- The risk of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE) persists following acute VTE treatment but may reduce over time for some patients  
- The EINSTEIN CHOICE study will investigate rivaroxaban 10 mg and 20 mg once daily for the long-term, secondary prevention of venous blood clots following acute DVT or PE treatment

February 14, 2014 Not intended for U.S. and UK Media  
**Bayer: Takeover offer for Algeta expires at 9:00 a.m. CET on February 24, 2014**  
- Cash offer of NOK 362 per Algeta share  
- Minimum acceptance level of 90 % of Algeta's share capital  
- Shareholders should contact their depositary bank immediately

February 14, 2014 Not intended for U.S. and UK Media - Acute Coronary Syndrome (ACS):  
**U.S. FDA Issues Complete Response Letters for Bayer's Xarelto® (Rivaroxaban) to reduce the Risk of Thrombotic Cardiovascular Events and Stent Thrombosis in Patients with ACS**

February 12, 2014 Not intended for U.S. and UK Media  
**"Green light" for Bayer's new transparent low dose contraceptive patch in the EU**

February 10, 2014 Not intended for U.S. and UK Media  
**Two-Year Results from Phase III Trial of VEGF Trap-Eye (aflibercept solution for injection) for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision**

January 24, 2014 Not intended for U.S. and UK Media  
**Bayer's Riociguat Recommended for Approval in the EU in Two Forms of Pulmonary Hypertension**  
- Riociguat is the first drug to consistently demonstrate efficacy in two life-threatening pulmonary hypertension (PH) indications - chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH)  
- Riociguat has been developed to target a key molecular mechanism underlying this serious disorder of the heart and lungs

January 21, 2014 **Bayer issues EUR 2 billion of bonds**  
Transaction comprises two-year floating-rate tranche and two EUR 750 million fixed-rate bonds with maturities of four and seven years

- January 20, 2014 Not intended for U.S. and UK media  
**Bayer commences takeover offer for all the shares of Algeta ASA**
- January 17, 2014 Not intended for U.S. and UK Media  
**Bayer Receives Approval for Riociguat in Japan for the Treatment of Chronic-Thromboembolic Pulmonary Hypertension**
- January 16, 2014 Not intended for U.S. and UK Media - Acute Coronary Syndrome (ACS):**U.S. FDA Advisory Committee Recommends Against Approval of Bayer's Xarelto® (Rivaroxaban) in Patients with ACS**
- January 13, 2014 Not intended for U.S. and UK Media - Ophthalmology Research:  
**Bayer and Regeneron to Develop New Treatment Option for Wet Age-Related Macular Degeneration**
- Joint development of Regeneron's PDGFR Beta antibody as new candidate for potential combination therapy demonstrates both companies' strong commitment to ophthalmology
  - Bayer obtains exclusive commercialization rights outside the U.S., where Bayer and Regeneron will share profits
  - Regeneron retains full U.S. commercialization rights